NASDAQ
18.09.26 | 21:01
0,720 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.08. | BeyondSpring GAAP EPS of -$0.02 | 1 | Seeking Alpha | ||
| 14.08. | BeyondSpring, Inc.: BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update | 397 | GlobeNewswire (Europe) | ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR... ► Artikel lesen | |
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 04.06. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | BeyondSpring names new CEO, CFO as founder shifts to chairman role | 1 | Investing.com | ||
| 04.06. | BeyondSpring, Inc.: BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value | 264 | GlobeNewswire (Europe) | Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer - a structure designed to give... ► Artikel lesen | |
| 02.06. | BeyondSpring reports phase 2 lung cancer trial results at ASCO | 1 | Investing.com | ||
| 02.06. | BeyondSpring, Inc.: BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor ... | 1 | GlobeNewswire (USA) | ||
| 18.05. | BeyondSpring, Inc.: BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13.05. | BeyondSpring Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | BeyondSpring Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.04. | BeyondSpring, Inc.: BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs | 1 | GlobeNewswire (USA) | ||
| 30.03. | BeyondSpring, Inc.: BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 25.03. | BeyondSpring, Inc.: BeyondSpring Files 2025 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
| 25.03. | BeyondSpring Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | BeyondSpring, Inc.: BeyondSpring Reports 2025 Year-End Financial Results | 213 | GlobeNewswire (Europe) | Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care... ► Artikel lesen | |
| 25.03. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.12.25 | BeyondSpring, Inc.: BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC | 508 | GlobeNewswire (Europe) | In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,360 | -3,28 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| TEMPUS AI | 67,70 | -0,09 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| IMMUNITYBIO | 7,380 | -0,27 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TRAWS PHARMA | 0,491 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| VERASTEM | 6,510 | +0,71 % | Verastem Oncology stellt auf Konferenz zweigleisige RAS-Strategie vor | ||
| CURIS | 0,880 | 0,00 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 3,470 | 0,00 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 1,430 | +1,42 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| BIOAGE LABS | 6,955 | -1,07 % | BioAge Labs: Fokus auf Wirkstoff BGE-102 trotz strategischer Neuausrichtung | ||
| CORMEDIX | 6,614 | -0,69 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen | |
| PRECIGEN | 6,800 | +0,74 % | Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock? | ||
| ALAUNOS THERAPEUTICS | 1,205 | +0,42 % | Alaunos Therapeutics Stock Falls 17% After Public Offering Announcement | ||
| NEOGENOMICS | 16,855 | -2,74 % | NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point |
Das Unternehmen BEYONDSPRING INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.